Boston Partners Purchases 758 Shares of Mesa Laboratories, Inc. $MLAB

Boston Partners raised its position in Mesa Laboratories, Inc. (NASDAQ:MLAB) by 16.3% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 5,421 shares of the medical instruments supplier’s stock after acquiring an additional 758 shares during the period. Boston Partners owned approximately 0.10% of Mesa Laboratories worth $511,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also bought and sold shares of MLAB. Select Equity Group L.P. boosted its position in shares of Mesa Laboratories by 439.0% in the 1st quarter. Select Equity Group L.P. now owns 73,897 shares of the medical instruments supplier’s stock worth $8,769,000 after purchasing an additional 60,186 shares in the last quarter. Nuveen LLC purchased a new stake in Mesa Laboratories in the first quarter valued at about $2,305,000. Raymond James Financial Inc. raised its stake in Mesa Laboratories by 6.5% in the first quarter. Raymond James Financial Inc. now owns 264,013 shares of the medical instruments supplier’s stock valued at $31,328,000 after buying an additional 16,218 shares during the last quarter. Geneva Capital Management LLC boosted its holdings in Mesa Laboratories by 5.2% in the second quarter. Geneva Capital Management LLC now owns 199,092 shares of the medical instruments supplier’s stock worth $18,758,000 after acquiring an additional 9,780 shares in the last quarter. Finally, AlphaQuest LLC grew its stake in shares of Mesa Laboratories by 9,667.7% during the second quarter. AlphaQuest LLC now owns 6,056 shares of the medical instruments supplier’s stock worth $571,000 after acquiring an additional 5,994 shares during the last quarter. 90.60% of the stock is owned by hedge funds and other institutional investors.

Mesa Laboratories Stock Down 2.5%

MLAB stock opened at $73.94 on Friday. The firm’s fifty day simple moving average is $71.52 and its 200-day simple moving average is $83.74. The company has a market capitalization of $408.30 million, a P/E ratio of -528.14 and a beta of 0.89. The company has a debt-to-equity ratio of 0.46, a current ratio of 0.66 and a quick ratio of 0.47. Mesa Laboratories, Inc. has a 12 month low of $55.45 and a 12 month high of $155.12.

Mesa Laboratories Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 15th. Shareholders of record on Friday, November 28th will be paid a dividend of $0.16 per share. The ex-dividend date is Friday, November 28th. This represents a $0.64 dividend on an annualized basis and a dividend yield of 0.9%. Mesa Laboratories’s dividend payout ratio (DPR) is presently -200.00%.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on MLAB. Zacks Research raised shares of Mesa Laboratories from a “strong sell” rating to a “hold” rating in a research report on Monday, August 18th. Wells Fargo & Company upgraded shares of Mesa Laboratories from an “underweight” rating to an “equal weight” rating and cut their price target for the company from $100.00 to $67.00 in a research note on Thursday, August 7th. Wall Street Zen upgraded shares of Mesa Laboratories from a “hold” rating to a “buy” rating in a research note on Saturday, November 8th. Finally, Weiss Ratings reissued a “sell (d)” rating on shares of Mesa Laboratories in a report on Wednesday, October 8th. Two analysts have rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Mesa Laboratories has a consensus rating of “Reduce” and a consensus target price of $67.00.

Mesa Laboratories Profile

Mesa Laboratories, Inc develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries.